Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kairos Pharma, Ltd. ( (KAPA) ) has issued an announcement.
On October 8, 2025, Kairos Pharma, Ltd.‘s Compensation Committee approved the grant of $950,000 in restricted stock units (RSUs) under its 2023 Equity Incentive Plan to certain executive officers and directors for their service from October 2025 to October 2026. The RSUs, calculated at a per share price of $1.31, will vest fully on October 8, 2026, and are subject to continuous service or immediate vesting upon a change in control. Additionally, cash bonuses totaling $227,500 were awarded for fiscal year 2024 performance, with key executives receiving varying amounts. This move aims to recognize and incentivize the company’s leadership, potentially impacting its operational focus and stakeholder confidence.
The most recent analyst rating on (KAPA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Average Trading Volume: 1,344,393
Technical Sentiment Signal: Buy
Current Market Cap: $25.1M
For a thorough assessment of KAPA stock, go to TipRanks’ Stock Analysis page.